# OnCo record alter-0303 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/alter-0303/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "alter-0303", "NCT02388919" ;
  schema:name "ALTER 0303"@en ;
  schema:description "The trial that showed anlotinib helps patients with lung cancer live longer after other treatments have failed, the basis of one of China's most used cancer pills."@en ;
  schema:url <https://onco.cc/trials/alter-0303/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02388919>, <https://doi.org/10.1001/jamaoncol.2018.3039> ;
  onco:status "positive" ;
  onco:tag "china" ;
  onco:phase "2/3" ;
  schema:startDate "2015-02-26" ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/antiangiogenic/> ;
  onco:drugs <https://onco.cc/drugs/anlotinib/> ;
  onco:companies <https://onco.cc/companies/sino-biopharm/> ;
  onco:institutions <https://onco.cc/institutions/shanghai-chest-hospital/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-alter-0303-jama-oncol-2018/> .